Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 1 of 15
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Washington University School of Medicine
NCT07109427
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
National Cancer Institute (NCI)
NCT03354416
Sample Collection for Ongoing Research and Product Evaluation Study
Natera
NCT07318051
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
UMC Utrecht
NCT04075305
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
McMaster University
NCT03127631
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Prostate Cancer Clinical Trials Consortium
NCT03151629
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
VA Office of Research and Development
NCT05926102
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
National Cancer Institute (NCI)
NCT02594202
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
University of Chicago
NCT06705803
Precision-Based Genomics in Prostate Cancer
National Cancer Institute (NCI)
NCT04706663
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
The New York Proton Center
NCT05313191
Collection of Blood From Patients With Cancer
National Cancer Institute (NCI)
NCT00034216
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
Memorial Sloan Kettering Cancer Center
NCT06954337
Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
Adam S. Kibel, MD
NCT06398639
African Cancer Genome: GMD
Fox Chase Cancer Center
NCT05754658
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Merck Sharp & Dohme
NCT06925737
Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
Albany Medical College
NCT06517901
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
National Cancer Institute (NCI)
NCT01441089
Video Education With Result Dependent dIsclosure
Dana-Farber Cancer Institute
NCT05225428
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
Endeavor Health
NCT05295407
Real World Prostate Cancer Registry
Cincinnati Cancer Advisors
NCT06355336
Customized TULSA-PRO Ablation Registry
Profound Medical
NCT05001477
Collection of Blood From Patients With Prostate Cancer
National Cancer Institute (NCI)
NCT00923221
Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer
NYU Langone Health
NCT07184957
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
University of California, San Francisco
NCT05056077
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Pfizer
NCT07028853
EDRN Prostate MRI Biomarker Study
University of Michigan
NCT03784924
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Novartis Pharmaceuticals
NCT06855277
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Global Development
NCT02960022
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
University of Michigan Rogel Cancer Center
NCT04396808
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Roswell Park Cancer Institute
NCT06563388
Cleveland African American Prostate Cancer Project
Case Comprehensive Cancer Center
NCT05469269
Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)
Northwestern University
NCT06804785
A Study of Changes to Prostate Procedures
Memorial Sloan Kettering Cancer Center
NCT06986083
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
National Cancer Institute (NCI)
NCT00451022
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Canadian Cancer Trials Group
NCT06235697
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
AstraZeneca
NCT06952803
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis Pharmaceuticals
NCT05803941
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Icahn School of Medicine at Mount Sinai
NCT05146297
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
yair lotan
NCT02064673
Clinical Trial of Approaches to Prostate Cancer Surgery
Weill Medical College of Cornell University
NCT05155501
Upright MRI for Prostate Cancer Screening
Icahn School of Medicine at Mount Sinai
NCT03474913
Evaluation of an Online Prostate Cancer Screening Decision Aid
David Siegel
NCT06610474
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
National Cancer Institute (NCI)
NCT04692675
Diffusion Basis Spectrum Imaging of the Prostate
Washington University School of Medicine
NCT04420702
Focal Therapy for Localized Prostate Cancer
University of California, San Diego
NCT06270043
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
Covenant Health Cancer Center
NCT06200259
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Prostate Cancer Clinical Trials Consortium
NCT04995198
ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
University of California, San Diego
NCT06579417
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
Johns Hopkins University
NCT02871726
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.